Clinical trials: Dementia Mild
Alzheimer Disease
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.
- Trial name
- NCT00663026
- Testing
- bapineuzumab
- Where
- 17 sites in United States
- Volunteers
- 79 people
- Sponsor
- Pfizer
Alzheimer Disease
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or…
- Trial name
- NCT04886063
- Testing
- ATH-1017
- Where
- United States
- Volunteers
- 423 people
- Sponsor
- LeonaBio
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Mild Cognitive Impairment
A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients
This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this…
- Trial name
- NCT01594541
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Pamlab, Inc.
Alzheimer Disease
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
The primary objective is to demonstrate that SR57667B at the dose of 4 mg/day, in comparison to placebo, decreases the decline in cognitive performance and the global clinical decline over 1 year in patients with mild to moderate…
- Trial name
- NCT00285025
- Testing
- SR57667B
- Volunteers
- 500 people
- Sponsor
- Sanofi
Alzheimer's Disease
Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's…
- Trial name
- NCT05811442
- Testing
- 50561 high dose, 50561 low dose
- Where
- 12 sites in China
- Volunteers
- 68 people
- Sponsor
- Beijing Joekai Biotechnology LLC
Mild Cognitive Impairment and Dementia
UK Validation of the Automated "AcceXible" Speech Analysis Software
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear.
- Trial name
- NCT05534958
- Testing
- Accexible
- Where
- United Kingdom
- Volunteers
- 221 people
- Sponsor
- Accexible
Alzheimer's Disease
Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease
1. Assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate Alzheimer's disease 2.
- Trial name
- NCT00744978
- Testing
- Varenicline
- Where
- 8 sites in South Korea
- Volunteers
- 66 people
- Sponsor
- Pfizer
Alzheimer Disease
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease.
- Trial name
- NCT05686044
- Testing
- Buntanetap/Posiphen
- Where
- 54 sites in United States
- Volunteers
- 351 people
- Sponsor
- Annovis Bio Inc.
Alzheimer's Disease
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.
- Trial name
- NCT02756858
- Testing
- ANAVEX2-73
- Where
- 5 sites in Australia
- Volunteers
- 21 people
- Sponsor
- Anavex Life Sciences Corp.
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
- Trial name
- NCT06199037
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer Disease
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe.
- Trial name
- NCT00380302
- Testing
- AVE1625
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 162 people
- Sponsor
- Sanofi
Alzheimer Dementia
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial.
- Trial name
- NCT07066826
- Testing
- Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Alzheimer Disease, Dementia of Alzheimer Type
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.
- Trial name
- LIFT-AD (NCT04488419)
- Testing
- ATH-1017
- Where
- United States
- Volunteers
- 554 people
- Sponsor
- LeonaBio
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP I (NCT05477056)
- Testing
- PrecivityAD blood test
- Where
- United States
- Volunteers
- 366 people
- Sponsor
- C2N Diagnostics
Alzheimer Disease
Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.
- Trial name
- NCT02991235
- Testing
- PRJ212
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Bioiberica
Alzheimer's Disease
A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's Disease (AD) or Mild to Moderate AD.
- Trial name
- NCT02127476
- Testing
- KHK6640
- Where
- 9 sites in Belgium, Finland and 3 more
- Volunteers
- 57 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Alzheimer's Disease
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00362024
- Testing
- MK0952
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind…
- Trial name
- NCT01238991
- Testing
- ACC-001
- Where
- 11 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Pfizer